Document is current
Any future updates will be listed below
-
Authors
Goloudina, Anastasia
Le Chevalier, Fabien
Authié, Pierre
Ciret, Sylvain
Nemirov, Kirill
Fert, Ingrid
Moncoq, Fanny
Vesin, Benjamin
Noirat, Amandine
Blanc, Catherine
Wei, Yu
Charneau, Pierre
Majlessi, Laleh
-
Funding
Funding for this research was provided by:
Intitut Pasteur
- License Information
-
More Information
Article History
Received: 17 March 2025
Accepted: 30 May 2025
First Online: 2 July 2025
Declarations
:
: PC is the founder and CSO of TheraVectys. AG, FLC, PA, KN, IF, FM, BV and AN are employees of TheraVectys. LM has a consultancy activity for TheraVectys. AG, FLC, IF, AN, CB, PC and LM are inventors of a pending patent directed to the potential of lentiviral vectors encoding KRAS mutations in immuno-oncotherapy. Other authors declare no competing interests.
